Eurofins Scientific SE

DB:ESF0 Stock Report

Market Cap: €9.1b

Eurofins Scientific Valuation

Is ESF0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ESF0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ESF0 (€47.15) is trading below our estimate of fair value (€144.1)

Significantly Below Fair Value: ESF0 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ESF0?

Key metric: As ESF0 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ESF0. This is calculated by dividing ESF0's market cap by their current earnings.
What is ESF0's PE Ratio?
PE Ratio27.9x
Earnings€325.90m
Market Cap€9.08b

Price to Earnings Ratio vs Peers

How does ESF0's PE Ratio compare to its peers?

The above table shows the PE ratio for ESF0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average65.1x
SRT3 Sartorius
192.8x35.2%€13.5b
1SXP SCHOTT Pharma KGaA
24.5x15.7%€3.7b
GXI Gerresheimer
20.4x21.8%€2.3b
DMP Dermapharm Holding
22.6x17.0%€2.0b
ESF0 Eurofins Scientific
27.9x18.4%€9.1b

Price-To-Earnings vs Peers: ESF0 is good value based on its Price-To-Earnings Ratio (27.9x) compared to the peer average (65.1x).

Price to Earnings Ratio vs Industry

How does ESF0's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
ESF0 27.9xIndustry Avg. 37.4xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ESF0 is good value based on its Price-To-Earnings Ratio (27.9x) compared to the European Life Sciences industry average (37.4x).

Price to Earnings Ratio vs Fair Ratio

What is ESF0's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ESF0 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.9x
Fair PE Ratio20.4x

Price-To-Earnings vs Fair Ratio: ESF0 is expensive based on its Price-To-Earnings Ratio (27.9x) compared to the estimated Fair Price-To-Earnings Ratio (20.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ESF0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€47.15
€59.46
+26.1%
21.5%€90.00€42.00n/a16
Dec ’25€46.15
€59.52
+29.0%
21.0%€89.00€42.00n/a16
Nov ’25€45.33
€59.52
+31.3%
21.0%€89.00€42.00n/a16
Oct ’25€57.50
€60.34
+4.9%
18.8%€90.00€44.00n/a16
Sep ’25€51.52
€59.91
+16.3%
18.6%€90.00€44.00n/a17
Aug ’25€54.66
€60.35
+10.4%
18.1%€90.00€44.00n/a17
Jul ’25€47.26
€59.69
+26.3%
17.1%€83.00€44.00n/a16
Jun ’25€55.34
€60.88
+10.0%
15.0%€83.00€48.00n/a16
May ’25€57.18
€60.88
+6.5%
15.0%€83.00€48.00n/a16
Apr ’25€58.76
€59.03
+0.5%
15.7%€84.00€48.00n/a16
Mar ’25€55.18
€58.66
+6.3%
14.5%€80.00€48.00n/a17
Feb ’25€56.46
€57.42
+1.7%
16.4%€80.00€45.00n/a17
Jan ’25€59.40
€57.65
-2.9%
16.4%€80.00€45.00n/a17
Dec ’24€53.88
€57.92
+7.5%
17.7%€81.00€45.00€46.1517
Nov ’24€48.03
€61.98
+29.0%
24.6%€105.00€45.00€45.3317
Oct ’24€54.00
€65.79
+21.8%
20.2%€105.00€48.00€57.5017
Sep ’24€56.74
€66.88
+17.9%
21.5%€105.00€48.00€51.5215
Aug ’24€62.36
€66.61
+6.8%
20.8%€105.00€48.00€54.6615
Jul ’24€57.30
€66.80
+16.6%
19.6%€105.00€50.00€47.2616
Jun ’24€61.16
€65.98
+7.9%
20.1%€105.00€50.00€55.3417
May ’24€63.02
€67.22
+6.7%
21.5%€105.00€50.00€57.1817
Apr ’24€61.96
€68.92
+11.2%
20.9%€105.00€50.00€58.7615
Mar ’24€58.20
€73.85
+26.9%
19.5%€105.00€51.92€55.1814
Feb ’24€66.28
€78.53
+18.5%
23.4%€125.00€51.92€56.4615
Jan ’24€67.92
€81.85
+20.5%
21.3%€125.00€51.92€59.4014
Dec ’23€68.46
€82.07
+19.9%
21.3%€125.00€51.92€53.8814

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eurofins Scientific SE is covered by 35 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ankush KathuriaAlphaValue
Pierre-Yves GauthierAlphaValue
Hubert D'AillieresBanco BPI, S.A.